Clinical Trials Browser

Mesothelioma, Malignant × VS-5584 × Clear all

NCT02372227 2017-01-30

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Phase 1 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant